Beyond Air (XAIR) Stock Analysis & Winston Score
Beyond Air is a medical device company that develops systems for delivering nitric oxide (NO) gas to patients. Nitric oxide helps open up blood vessels in the lungs and is used to treat newborns with breathing problems, a condition called persistent pulmonary hypertension. The company's main product, the LungFit system, generates nitric oxide from regular air rather than requiring heavy, expensive gas cylinders. Beyond Air earns revenue by selling and placing its LungFit devices in hospitals, along with related disposable components. The company is based in the United States and is still very small, with a market cap well under $100 million. Its key competitive advantage is the ability to generate nitric oxide on-demand from ambient air, which could be simpler and cheaper than traditional cylinder-based delivery. However, the company is not yet profitable, burns significant cash, and faces the major risk of needing to grow hospital adoption quickly enough to reach sustainable revenue levels.
Winston Score: 23/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Strong (15/20)
- Cash Flow: Weak (0/10)
- Stability: Weak (0/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $3.62
Market Cap: $3M
Sector: Healthcare
Industry: Medical - Devices
Exchange: NASDAQ Capital Market
